ki-67 index after neoadjuvant et as a prognostic biomarker for hr /her2- early breast cancer
Published 1 year ago • 2K plays • Length 6:09Download video MP4
Download video MP3
Similar videos
-
1:52
dr. ellis discusses ki67 as a treatment monitoring biomarker
-
2:13
changes in tumour biomarkers after neoadjuvant chemotherapy in breast cancer
-
10:05
ki-67 shows proven clinical utility as a predictive clincal biomarkers for breast cancer
-
1:21
the use of the ki-67 in deciding which patients with hr breast cancer can safely avoid chemotherapy
-
1:17
perelisa: de-escalated therapy for hr /her2 bc with ki67 response following 2-week letrozole
-
5:34
neos: prognosis of er breast cancer pts who received neoadjuvant et with/without adjuvant chemo
-
2:07
lumina results: women with low levels of the ki67 biomarker can avoid outcomes related to rt
-
2:25
comment: lumina results show that women with low levels of the ki67 biomarker can avoid outcomes...
-
2:05
important considerations in the management of hr , her2-negative early breast cancer
-
2:27
neoaltto: her2/cep17 ratio as a predictive biomarker in her breast cancer
-
2:32
neoadjuvant biomarker analysis of neorhea: palbociclib in er /her2- bc
-
1:19
dr. nielsen on the pros and cons of the ki67 assay in breast cancer
-
3:01
alternate: neoadjuvant chemotherapy in er her2- breast cancer
-
2:09
tumour biomarker changes after neoadjuvant chemotherapy in breast cancer
-
1:38
role of ki 67 index in grading of mtc
-
2:09
hrd, rb-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in hr /her2- early bc
-
1:01
dr. nielsen on the challenges of using ki67 as a tool in breast cancer
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
2:31
ki67, what is it and why is it controversial?